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Table　1　Characteristics of the study subjects
Healthy controls Allergic nonasthmatics Allergic asthmatics
Patients n 14 14 19
Age (yr) 25.4 ± 1.1 25.6 ± 1.9 35.4 ± 4.7
Males (n)  5  6 10
Females (n)  9  8  9
FEV1 % pred 99.4 ± 2.5 97.0 ± 4.2 94.6 ± 4.0
Methacholine PC20 mg/mL >32 >32 0.94 (0.33)**
Total IgE IU/mL 20.7 ± 5.4 131.2 ± 31.3  214.1 ± 56.9*
Systemic steroids  0  0  0
ICS  0  0  7
Beta2-agonist  0  0  7
Theophylline  0  0  0
LTRA  0  0  5
No drug treatment 14 14 12
Data are presented as n, mean ± SEM or mean (geometric SEM), unless otherwise stated. FEV1, forced expiratory volume in 1 s; % pred, 
% predicted; PC20, provocative concentration causing a 20% decrease in FEV1; Ig, immunoglobulin; ICS, Inhaled Corticosteroids; LTRA, 
Leuko Triene Receptor Antagonist. *p < 0.05 versus healthy controls; **p < 0.01 versus healthy controls and allergic nonasthmatics.
Dear Editor
Increased Serum Levels of Soluble IL-18
Receptor Complex in Patients with
Allergic Asthma
The inflammatory process in allergic asthma is initi-
ated by T-helper 2 (Th2) CD4+ cells, which produce a
repertoire of cytokines including IL-4, IL-5, IL-9 and
IL-13. These Th2 cytokines play a critical role in IgE
production, airway eosinophilia, and goblet cell hy-
perplasia. Many previous studies have shown that ac-
tivated CD4+ T cells, producing Th2 cytokines, are in-
creased in the airways of patients with mild asthma.1
In contrast, IFN-γ-producing Th1 cells are thought to
prevent asthma disease activity, although in some ex-
perimental models, Th1 cells have not suppressed
Th2 cell-mediated AHR and pulmonary inflamma-
tion.1
IL-18 is known to play an important role in Th1
Tc1 polarization, and promoting the production of
Th2 cytokines (e.g. IL-4, IL-5, IL-9, and IL-13) by T
cells, NK cells, basophils, and mast cells. Recent
studies have reported that IL-18 plays a key role in
the pathogenesis of pulmonary inflammatory dis-
eases including interstitial lung diseases and chronic
obstructive pulmonary disease (COPD).2 The IL-18
receptor (IL-18R) complex is composed of the IL-18
Rα and IL-18Rβ chains. IL-18Rα (IL-1R5IL-1Rrp1) is
the extracellular signaling domain,3 whereas IL-18Rβ
(IL-R7accessory protein-like [AcPL]IL-18R acces-
sory protein [AP]) is an adaptor molecule 4 in the
complex. We have reported the presence of a soluble
IL-18Rα complex in serum that exhibits antagonistic
activity in vitro, and contains a diametric IL-18 protein
and the soluble form of the IL-18Rβ chain. In addi-
tion, the serum levels of soluble IL-18Rα complex in
rheumatoid arthritis (RA) and adult-onset Still’s dis-
ease are significantly higher than those in healthy
controls.5 However the roles of soluble IL-18R com-
plex in allergic asthma remain unclear. Therefore, in
this study we measured the serum levels of soluble
IL-18R complex in patients with allergic asthma.
We obtained serum samples from 19 age-matched
subjects with allergic asthma, 14 allergic non-
asthmatic subjects, and 14 healthy controls (Table 1).
All subjects underwent a methacholine inhalation
challenge and skin prick tests using a panel of 16 en-
vironmental allergens, as reported previously. 6
Ninety-eight COPD patients and 36 age-matched
smokers and 51 age-matched nonsmokers were en-
rolled at Kurume University Hospital ( Kurume,
Fukuoka, Japan). Soluble IL-18R complex was meas-
ured using a method we had employed previously.5
The limit of sensitivity of this ELISA system was <5
ngmL. The serum level of IgE was measured using
commercially available ELISA kits (Minneapolis, MN,
USA). Results are expressed as means ± standard er-
ror of the mean ( SEM ) . Nonparametric tests
( Kruskal-Wallis and Mann-Whitney U-tests ) were
used to compare differences between the groups.
Correlations were analyzed by simple regression.
The level of statistical significance was set at p < 0.05.
The SAS 9.1.3 software package, Japanese edition
(SAS Institute, Cary, NC, USA), was used for statisti-
cal analysis.
The serum levels of the IL-18Rα protein complex in
the 19 subjects with allergic asthma, 14 allergic non-
asthmatic subjects and 14 healthy controls were 32.9
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Fig.　1　(A) Serum levels of interleukin (IL)-18 receptor α complex in healthy controls (n = 15), allergic nonasthmatics (n = 14) 
and allergic asthmatics (n = 19). *p < 0.01. (B) Correlation between serum levels of interleukin (IL)-18 receptor α complex and 
IgE in subjects overall (n = 47). p < 0.001, R = 0.4137.
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+ 4.3, 18.8 + 1.5, and 16.1 + 1.6 ngmL, respectively.
The serum levels of the IL-18Rα complex in the aller-
gic asthmatics were significantly (p < 0.01) higher
than those in the allergic non-asthmatic subjects and
healthy controls. In contrast, the serum levels of the
IL-18Rα complex in the allergic non-asthmatic sub-
jects were not significantly higher than those in
healthy controls (Fig. 1A). Moreover, the serum lev-
els of IL-18Rα complex were positively and signifi-
cantly correlated with the serum levels of IgE in the
subjects overall (n = 47) (p < 0.001, R = 0.4137) (Fig. 1
B). However, there was no significant association be-
tween the serum levels of IL-18Rα complex and IL-18
protein (data not shown). Moreover, there was no
correlation between the serum levels of IL-18Rα com-
plex and pulmonary function (FEV1) or airway hyper-
responsiveness (Methacholine PC20 mgmL) (data
not shown). Using receiver operating characteristic
(ROC) curve analysis, we evaluated whether the se-
rum levels of the IL-18Rα complex could discriminate
patients with allergic asthma from allergic non-
asthmatics and healthy controls. The area under the
ROC curve for the serum level of the IL-18Rα com-
plex was 0.863. At a cut-off point of 19.0 ngml, the
specificity was 0.679 and the sensitivity was 0.895 for
detection of allergic asthma, suggesting that serum
levels of soluble IL-18Rα complex may discriminate
such patients. Further studies will be needed to verify
this issue. Next, we examined the serum level of the
sIL-18R complex in 98 COPD patients and 36 age-
matched smokers and 51 nonsmokers. The mean age
of COPD, smokers, and nonsmokers was 66.5 ± 9.4,
61.2 ± 2.4, and 62.1 ± 2.3 years, respectively. There
was no significant difference of age among 3 groups.
The serum levels of sIL-18R complex were 42.1 ± 8.2,
53.1 ± 17.5, and 58.6 ± 11.8 ngmL, respectively. In-
terestingly, the serum levels of sIL-18R complex in
nonsmokers were significantly (p < 0.05) higher than
smokers and COPD patients but there was no signifi-
cant difference between COPD patients and smokers.
In this study, we could not compare the serum levels
of sIL-18R complex between allergic asthmatics and
COPD patients, because the mean age of allergic
asthma patients (35.4 ± 4.7 years) was significantly (p
< 0.05) lower than that of COPD patients (66.5 ± 9.4
years). Further studies are needed to clarify the rea-
sons why serum levels of sIL-18R complex are de-
creased in COPD patients.
Serum levels of IL-18 are higher in asthmatic sub-
jects when compared to healthy controls. In addition,
significantly higher serum IL-18 levels have been re-
ported in patients with acute severe asthma. 1 Poly-
morphism of the IL-18 gene has been associated with
asthma severity, the rs5744247 variant reflecting both
higher transcriptional activity and higher serum IL-18
levels.7 In addition, the IL-18R gene (on 2q21) has
been identified as a candidate gene associated with
increased susceptibility to asthma in children,8 and
polymorphisms of the gene are related to allergic
asthma and airway hyper-responsiveness (AHR).9 Re-
cently, we reported that IL-18Rα protein was ex-
pressed in the airway epithelium of patients with al-
lergic asthma.6 Soluble IL-18Rα complex exhibits an-
tagonistic activity in vitro.5 IL-18 can act as a cofactor
for Th2 cell development and IgE production.10 IL-18
may increase the level of IgE in sera. Therefore, in-
creased levels of soluble IL-18Rα complex in serum
may also exert an antagonistic effect in vivo and play
an important role in the inflammatory process in aller-
gic asthma.
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